Spark Therapeutics Announces Closing of Its Initial Public Offering
A registration statement relating to these securities was declared effective by the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
Spark is a late clinical-stage gene therapy company seeking to develop one-time, life-altering treatments for debilitating genetic diseases, with an initial focus on treating rare diseases. Spark's most advanced product candidate, SPK-RPE65, which has received both breakthrough therapy and orphan product designation, is in a fully-enrolled pivotal Phase 3 clinical trial for the treatment of a rare blinding condition. Spark also has product candidates in development for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spark-therapeutics-announces-closing-of-its-initial-public-offering-300030860.html
Stephen Webster, 215-220-9327